Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O60941
UPID:
DTNB_HUMAN
Alternative names:
Beta-dystrobrevin
Alternative UPACC:
O60941; B7Z733; F5GZG4; G5E9F6; O43782; O60881; O75538; Q86VR4; Q96AW0; Q9UE14; Q9UE15; Q9UE16
Background:
Dystrobrevin beta, alternatively known as Beta-dystrobrevin, plays a crucial role in cellular architecture, particularly in the assembly of DMD and SNTA1 molecules to the basal membrane of kidney cells and liver sinusoids. It is implicated in the regulation of SYN1 expression through binding to the repressor element-1 (RE-1), influencing cell proliferation during early neural differentiation. Additionally, it is essential for the maturation and function of a subset of inhibitory synapses.
Therapeutic significance:
Understanding the role of Dystrobrevin beta could open doors to potential therapeutic strategies, especially in the context of neural differentiation and synaptic function.